drugset / Trial / NCT05577923
Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower)
NaSingle-groupOpen-labelTreatment
Summary
This study is a prospective, single-arm, phase II clinical study for patients with ER+/HER2+ advanced breast cancer.
Timeline
- Start
- 2022-11-01
- Primary completion
- 2024-09-01
- Completion
- 2026-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dalpiciclib | Small molecule | 125 mg | Oral |
| Subject | Fulvestrant | Small molecule | 500 mg | Intramuscular |
| Subject | Pyrotinib | Small molecule | 320 mg | Oral |
| Subject | Trastuzumab | Monoclonal antibody | 6 mg/kg | Intravenous |